✦ LIBER ✦

Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results

✍ Scribed by Kefford, Richard; Sullivan, Ryan J; Miller, Wilson H; Elez, Elena M; Tan, Daniel; Kim, Kevin B; Long, Georgina V; Flaherty, Keith T; Tai, David; Stutvoet, Simone; Maacke, Heiko; Whiley, Matt; Parseval, Laure; Tabernero, Josep

Book ID: 125401244
Publisher: BioMed Central
Year: 2014
Tongue: English
Weight: 91 KB
Volume: 12
Category: Article
ISSN: 1479-5876
DOI: 10.1186/1479-5876-12-S1-P5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

608 Phase I Dose-escalation Trial of a S

608 Phase I Dose-escalation Trial of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B), Combined with an mTOR Inhibitor, Temsirolimus, in Patients with Advanced Solid Tumors

✍ Naing, A.; Mita, M.; Komarnitsky, P.; Milner, A.; von Richter, O.; Ogden, J.; Pi 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 64 KB

282 POSTER Preliminary results of a Phas

282 POSTER Preliminary results of a Phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral Aurora kinase A and B inhibitor, in patients with advanced solid tumors

✍ P. Schöffski; H. Dumez; S.F. Jones; C. Fowst; P. Gerletti; H. Xu; J. Jakubczak; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 64 KB